{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:07:32Z","timestamp":1761808052141,"version":"build-2065373602"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:p>Hepatitis C virus (HCV) is the most common blood\u2010borne infection in the United States. The high morbidity and mortality due to untreated infection have prompted updated screening recommendations that now include one\u2010time HCV screening for all patients born between 1945 and 1965, in addition to risk factor\u2013based screening. Current guidelines recommend treatment for all patients with chronic HCV. Treatment for HCV genotype 1 has evolved dramatically since the approval of the direct\u2010acting antivirals. The approval of ledipasvir\u2010sofosbuvir, ombitasvir\u2010paritaprevir\u2010ritonavir and dasabuvir, and simeprevir with sofosbuvir has dramatically altered the treatment landscape. High sustained virologic response (SVR) rates favor treatment, yet access to care poses a challenge for patients and providers. Current and emerging data with new therapies indicate high SVR rates in treatment\u2010na\u00efve and treatment\u2010experienced patients, including patients with cirrhosis and in other special populations. Additional data suggest the addition of ribavirin can decrease treatment duration without compromising SVR rates. Resistance is an increasing area of interest in HCV, with baseline mutations identified and the potential for the development of resistance\u2010associate variants in patients undergoing treatment. Due to the rapid evolution of HCV treatment, pharmacists should address challenges and play an integral role in agent selection, dosing, drug interaction screening, adverse effect monitoring, and the coordination of treatment. Clinical application of the latest information will reduce patient risk and improve outcomes.<\/jats:p>","DOI":"10.1002\/phar.1700","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T02:50:16Z","timestamp":1454640616000},"page":"203-217","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Therapeutic Advances in <scp>HCV<\/scp> Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists"],"prefix":"10.1002","volume":"36","author":[{"given":"Paulina","family":"Deming","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice University of New Mexico College of Pharmacy Albuquerque New Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle T.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice University of Illinois at Chicago College of Pharmacy University of Illinois Hospital and Health Sciences System Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Chan","sequence":"additional","affiliation":[{"name":"Colleges of Pharmacy and Medicine University of Illinois at Chicago Chicago Illinois"},{"name":"Gastroenterology\/Hepatology Illinois Department of Corrections Hepatology Telemedicine Sections of Hepatology, Digestive Diseases and Nutrition University of Illinois Hospital &amp; Health Sciences Center Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Dilworth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Wheaton Franciscan Healthcare \u2013 St. Francis Milwaukee Wisconsin"},{"name":"Center for AIDS Intervention Research Medical College of Wisconsin Milwaukee Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"El\u2010Lababidi","sequence":"additional","affiliation":[{"name":"Pharmacy Education and Training Department of Pharmacy Services Cleveland Clinic Abu Dhabi Abu Dhabi UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-9143","authenticated-orcid":false,"given":"Bryan L.","family":"Love","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Outcomes Sciences South Carolina College of Pharmacy Columbia South Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima A.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Clinical, Social, and Administrative Sciences University of Michigan College of Pharmacy Ann Arbor Michigan"},{"name":"University of Michigan Health System Ann Arbor Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Gallup Indian Medical Center Gallup New Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Spooner","sequence":"additional","affiliation":[{"name":"Pharmacy Practice School of Pharmacy Worcester\/Manchester MCPHS University Worcester Massachusetts"},{"name":"Infectious Diseases Saint Vincent Hospital Worcester Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne B.","family":"Wortman","sequence":"additional","affiliation":[{"name":"Penn Highlands DuBois DuBois Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.067"},{"key":"e_1_2_15_3_1","unstructured":"AASLD\/IDSA\/IAS\u2013USA.Recommendations for testing managing and treating hepatitis C. Available fromhttp:\/\/www.hcvguidelines.org. Accessed April 24 2015."},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"e_1_2_15_5_1","unstructured":"World Health Organization.Guidelines for the Screening Care and Treatment of Persons with Hepatitis C Infection. Available fromhttp:\/\/www.ncbi.nlm.nih.gov\/books\/NBK263483\/Accessed February 1 2015."},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1133"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis361"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02494.x"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1302973"},{"issue":"04","key":"e_1_2_15_10_1","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among people born between 1945\u20131965","volume":"61","author":"Smith BD","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_15_11_1","first-page":"15","article-title":"The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease","volume":"21","author":"Ward JW","year":"2013","journal-title":"Top Antivir Med"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2012-050566"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.05.006"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24105"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.407"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/474S5a"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1328"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70050-2"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27826"},{"key":"e_1_2_15_30_1","unstructured":"WylesDL PockrosPJ YangJC et\u00a0al.Retreatment of patients who failed prior sofosbuvir\u2010based regimens with all oral fixed\u2010dose combination ledipasvir\u2010sofosbuvir plus ribavirin for 12\u00a0weeks. [Abstract 235]. 65th Annual Meeting for the American Association for the Study of Liver Diseases; November 7\u201311 2014; Boston MA."},{"key":"e_1_2_15_31_1","unstructured":"FlammSL EversonGT CharltonM et\u00a0al. Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective multicenter study. [Abstract 239] 65th Annual Meeting for the American Association for the Study of Liver Diseases; November 7\u201311 2014; Boston MA."},{"key":"e_1_2_15_32_1","unstructured":"National Center for HIV\/AIDS Viral Hepatitis STD and TB Prevention.Division of HIV\/AIDS Prevention. HIV and Viral Hepatitis Factsheet. March 2014. Available fromhttp:\/\/www.cdc.gov\/hiv\/pdf\/library_factsheets_HIV_and_viral_Hepatitis.pdf. Accessed March 5 2015."},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/427216"},{"key":"e_1_2_15_34_1","unstructured":"OsinsuiA TownsendK NelsonA et\u00a0al.Use of ledipasvir\/sofosbuvir fixed dose combination for treatment of HCV genotype\u20101 infection in patients coinfected with HIV\u2010ERADICATE study. [Abstract 84]. 65th Annual Meeting for the American Association for the Study of Liver Diseases; November 7\u201311 2014; Boston MA."},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21646"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25976"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.023"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250529"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.393"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.10.009"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.08.133"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355615"},{"volume-title":"Sovaldi (sofosbuvir) package insert","year":"2015","author":"Gilead Sciences, Inc","key":"e_1_2_15_45_1"},{"key":"e_1_2_15_46_1","unstructured":"GaneEJ RobsonRA BonaciniM et\u00a0al.Safety antiviral efficacy and pharmacokinetics of sofosbuvir in patients with severe renal impairment. [Abstract 966] 65th Annual Meeting for the American Association for the Study of Liver Diseases; November 7\u201311 2014; Boston MA."},{"key":"e_1_2_15_47_1","first-page":"151","article-title":"The critical need for pharmacist involvement in the management of patients with hepatitis C","volume":"15","author":"Spooner LM","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1512"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26246"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.300858"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009370"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1700","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:02:02Z","timestamp":1761040922000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1002\/phar.1700"],"URL":"https:\/\/doi.org\/10.1002\/phar.1700","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"2016-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}